DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials

BACKGROUND: Because the general population is largely naive to H5N1 influenza, antibodies generated to H5 allow analysis of novel influenza vaccines independent of background immunity from previous infection. We assessed the safety and immunogenicity of DNA encoding H5 as a priming vaccine to improv...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Lancet Infect Dis
Autori principali: Ledgerwood, Julie E, Wei, Chih-Jen, Hu, Zonghui, Gordon, Ingelise J, Enama, Mary E, Hendel, Cynthia S, McTamney, Patrick M, Pearce, Melissa B, Yassine, Hadi M, Boyington, Jeffrey C, Bailer, Robert, Tumpey, Terrence M, Koup, Richard A, Mascola, John R, Nabel, Gary J, Graham, Barney S
Natura: Artigo
Lingua:Inglês
Pubblicazione: Elsevier Ltd. 2011
Soggetti:
Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7185472/
https://ncbi.nlm.nih.gov/pubmed/21975270
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1473-3099(11)70240-7
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi